NCT03991091View on ClinicalTrials.gov

Reducing Neonatal Morbidity by Discontinuing Oxytocin During the Active Phase of 1st Stage of Labor

PHASE4CompletedINTERVENTIONAL
Enrollment

2,459

Participants

Timeline

Start Date

January 17, 2020

Primary Completion Date

April 25, 2022

Study Completion Date

April 25, 2022

Conditions
Neonatal Morbidity
Interventions
DRUG

discontinuation of oxytocin administration

Discontinuation of oxytocin administration at the beginning of the active phase of the 1st stage of labor, i.e. oxytocin infusion will be stopped beyond a cervical dilatation of 6cm. In the experimental group, oxytocin can be re-started, if necessary, after 2 hours of arrest of labor.

DRUG

continuation of oxytocin administration

continuation of oxytocin administration

Trial Locations (1)

75014

hospital Cochin; port royal Maternity unit, Paris

All Listed Sponsors
collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT03991091 - Reducing Neonatal Morbidity by Discontinuing Oxytocin During the Active Phase of 1st Stage of Labor | Biotech Hunter | Biotech Hunter